Company: NDRA
Filing Date: 2025-11-26
Form Type: 424B4
Source: 0001213900-25-115097
Chunk: 13

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-11-26
Form: 424B4
Chunk 13
---
 a low of $2.90 to a high of $11.96 and may
continue to fluctuate significantly in the future. The stock market in general and the market for healthcare companies in particular
have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of
this volatility, investors may experience losses on their investment in our common stock. Additionally, we intend to use the majority
of the proceeds from this offering to purchase cryptocurrency, which has been, and will likely continue to be, volatile. When a material
portion of our assets is represented by cryptocurrency, our stock price will likely fluctuate based on the price of cryptocurrency.

<div align='center'>5</div>

Additionally, securities
of certain companies have experienced significant and extreme volatility in stock price due to a sudden increase in demand for stock
resulting in aggregate short positions in the stock exceeding the number of shares available for purchase, forcing investors with short
exposure to pay a premium to repurchase shares for delivery to share lenders. This is known as a “short squeeze.” These short
squeezes have led to the price per share of those companies to trade at a significantly inflated rate that is disconnected from the underlying
value of the company. Many investors who have purchased shares in those companies at an inflated rate face the risk of losing a significant
portion of their original investment as the price per share declines steadily as interest in those stocks abates. While we have no reason
to believe our shares would be the target of a short squeeze, there can be no assurance that they will not be in the future, and you
may lose a significant portion or all of your investment if you purchase our shares at a rate that is significantly disconnected from
our underlying value.

Risks Related to the Company’s DAT Strategy and Cryptocurrency

Our financial results and the market
price of our common stock may be affected by the prices of HYPE and any other digital assets we may hold.

As part of our capital
allocation strategy for assets that are not required to provide working capital for our ongoing operations, we have invested and
plan to continue to invest in HYPE. As of the date of this prospectus, we hold approximately 78,863.1 HYPE tokens. The price of HYPE has historically been subject to dramatic price fluctuations and is highly volatile. Moreover,
digital assets, such as HYPE, are relatively novel and the application of securities laws and other regulations to such assets is
unclear in many